Condition: Hepatocellular Carcinoma · Sponsor: Zhongda Hospital
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies.
This description comes directly from the study's public registry record.
Gao-Jun Teng, M.D · +86-02583272121 · gjteng@vip.sina.com
Hai-Dong Zhu, M.D · +86-02583272121 · zhuhaidong9509@163.com
Always discuss trial participation with your own doctor first.
| Zhongda Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06607120